High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M LegrosR Plagne

Abstract

A series of 53 patients with poor-prognosis epithelial ovarian cancer treated with high-dose chemotherapy (HDC) followed by hematopoietic rescue was retrospectively studied from the day of diagnosis for toxicity and long-term survival analysis. Patients were treated with surgery followed by cisplatin combination chemotherapy. After second-look operation (SLO), HDC was administered: 23 patients received melphalan (140 mg/m2 on day 1) and 30 patients received a combination of carboplatin (400 mg/m2 on days 1 to 4) and cyclophosphamide (1.6 g/m2 on days 1 to 4). After HDC, autologous stem-cell transplantation was performed for hematologic support. One patient died of cardiac failure after HDC, but the acute toxicity was acceptable for the other patients. With a median follow-up of 81.5 months, the 5-year overall survival rate for the 53 patients was 59.9% and the disease-free survival (DFS) rate at 5 years was 23.6%. Twenty-four patients (45.3%) were alive, 12 with no evidence of disease and 12 with recurrent disease. The best results were achieved in 19 patients with pathologic complete response at SLO (74.2% 5-year overall survival; 32.8% 5-year DFS). HDC followed by autologous stem-cell support is a well-tolerated therapeutic a...Continue Reading

Citations

Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jonathan A Ledermann
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Mar 29, 2000·Bone Marrow Transplantation·J O BayD Blaise
Feb 28, 2006·Bone Marrow Transplantation·J-P LotzUNKNOWN Groupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group)
Apr 11, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J A Ledermann
Oct 18, 2012·Journal of Experimental & Clinical Cancer Research : CR·Renaud SabatierJean-Marc Extra
Feb 27, 1999·Current Opinion in Obstetrics & Gynecology·S L McAfee, M V Seiden
Mar 6, 2003·Journal of Cancer Research and Clinical Oncology·M HänelF Kroschinsky
Sep 19, 2006·Bone Marrow Transplantation·N FrickhofenUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)
Jan 6, 2010·International Journal of Cancer. Journal International Du Cancer·Jacques-Olivier BayMarco Bregni
May 5, 2001·Expert Opinion on Pharmacotherapy·G H Eltabbakh, C S Awtrey
Mar 4, 1998·Current Opinion in Obstetrics & Gynecology·L M Chen, J S Berek
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J SchilderR F Ozols
Apr 10, 2008·Nature Clinical Practice. Oncology·Taner DemirerUNKNOWN EBMT Solid Tumors Working Party
Apr 27, 2004·Bone Marrow Transplantation·M MagagnoliA Santoro
Sep 16, 2004·Springer Seminars in Immunopathology·Yago NietoElizabeth J Shpall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.